Pancreatic Cancer Research

ResearcherCornell UniversityActive in the last 2 years

Jeffrey A. Drebin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2312-2062; OpenAlex author ID A5079031946. Sources: OpenAlex.

Their work

Papers
33 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
161
Papers, trials and grants by year

2012: 1 paper · 2013: 2 papers · 2014: 1 paper · 2015: 2 papers · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: 1 paper · 2021: 5 papers · 2022: 5 papers · 2023: 2 papers · 2024: 1 paper · 2025: 7 papers · 2026: 1 paper

Papers 33

  1. Maximal Ablative Irradiation Because of Encasement for Patients With Locally Advanced Pancreatic Cancer: A Nonrandomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2026.2988↗
  2. Influence of biologic sex and obesity on liver recurrence and survival in patients undergoing upfront surgery for pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.70088↗
  3. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08508-4↗
  4. Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort. Co-author DOI 10.1093/jnci/djae269↗
  5. Genome-based classification of pancreatic acinar cell carcinoma reveals similarities to KRAS wild-type PDAC. Co-author DOI 10.1186/s12967-025-07381-7↗
  6. Impact of Financial Toxicity on Treatment Adherence and Quality of Life in Pancreatic Cancer. Co-author DOI 10.1200/op-24-00528↗
  7. Outcomes in Locally Advanced Pancreatic Cancer After Induction Ablative Radiation Therapy and Resection. Co-author DOI 10.1245/s10434-025-17199-8↗
  8. Radiomics in sporadic microsatellite instable, mismatch repair deficient and Lynch syndrome-associated pancreatic ductal adenocarcinoma: a pilot study. Co-author DOI 10.3389/fonc.2025.1584167↗
  9. Salvage Ablative Radiotherapy for Isolated Local Recurrence of Pancreatic Adenocarcinoma following Definitive Surgery. Co-author DOI 10.3390/jcm13092631↗
  10. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Co-author DOI 10.1038/s41586-023-06063-y↗
  11. Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-22-3089↗
  12. Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.26735↗
  13. Development and validation of the Massachusetts General Hospital/Memorial Sloan Kettering nomogram to predict overall survival of resected patients with pancre… Co-author DOI 10.1016/j.surg.2022.05.024↗
  14. Alterations in Somatic Driver Genes Are Associated with Response to Neoadjuvant FOLFIRINOX in Patients with Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/xcs.0000000000000212↗
  15. Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Treatment Does Not Predict Pathological Response and Survival in Resectable Pancreatic Ductal Adeno… Co-author DOI 10.1177/0003134821989050↗
  16. Recurrence After Resection of Pancreatic Cancer: Can Radiomics Predict Patients at Greatest Risk of Liver Metastasis? Co-author DOI 10.1245/s10434-022-11579-0↗
  17. Contemporary Reappraisal of Intraoperative Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Review. Co-author DOI 10.1001/jamasurg.2020.5676↗
  18. Treatment patterns and survival in patients with early-onset pancreatic cancer. Co-author DOI 10.1002/cncr.33664↗
  19. Preoperative CT predictors of survival in patients with pancreatic ductal adenocarcinoma undergoing curative intent surgery. Co-author DOI 10.1007/s00261-020-02726-w↗
  20. Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000854↗
  21. Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement. Co-author DOI 10.1097/sla.0000000000005080↗
  22. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cncr.33038↗
  23. Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2019.0684↗
  24. CT radiomics associations with genotype and stromal content in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00261-019-02112-1↗
  25. Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma. Co-author DOI 10.1073/pnas.1914915116↗
  26. A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer. Co-author DOI 10.1007/s00280-018-3519-6↗
  27. Clinical study of genomic drivers in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/bjc.2017.209↗
  28. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Co-author DOI 10.1038/ncomms8686↗
  29. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Co-author DOI 10.1158/0008-5472.can-14-2211↗
  30. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Co-author DOI 10.1016/j.cell.2014.08.007↗
  31. Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally a… Co-author DOI 10.1007/s00280-013-2147-4↗
  32. A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma. First author DOI 10.1111/j.1477-2574.2012.00571.x↗
  33. Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer. Last author DOI 10.3892/or.2012.2053↗

Closest collaborators

The 25 strongest of 161 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. William R. Jarnagin · 20 shared papers, 2019–2026 · strength 3.07
  2. Michael Ian D'Angelica · 19 shared papers, 2019–2026 · strength 2.90
  3. Alice Chia-Chi Wei · 16 shared papers, 2021–2026 · strength 2.68
  4. Vinod P. Balachandran · 16 shared papers, 2019–2026 · strength 2.42
  5. Kevin C. Soares · 13 shared papers, 2021–2026 · strength 2.23
  6. Eileen Mary O'Reilly · 13 shared papers, 2020–2026 · strength 1.97
  7. T. Peter Kingham · 14 shared papers, 2019–2025 · strength 1.92
  8. Anna M. Varghese · 10 shared papers, 2020–2026 · strength 1.51
  9. Wungki Park · 7 shared papers, 2020–2026 · strength 1.11
  10. Christopher H. Crane · 6 shared papers, 2021–2026 · strength 1.04
  11. Kenneth H. Yu · 6 shared papers, 2020–2026 · strength 0.88
  12. Caitlin A. McIntyre · 7 shared papers, 2019–2025 · strength 0.86
  13. T. Peter Kingham · 4 shared papers, 2025–2026 · strength 0.84
  14. Marsha Reyngold · 4 shared papers, 2021–2026 · strength 0.72
  15. Peter J. Allen · 5 shared papers, 2015–2022 · strength 0.45
  16. Peter J. Allen · 3 shared papers, 2021–2025 · strength 0.43
  17. Alex B. Blair · 2 shared papers, 2025 · strength 0.43
  18. Quisette P. Janssen · 3 shared papers, 2022–2023 · strength 0.43
  19. Jayasree Chakraborty · 3 shared papers, 2019–2025 · strength 0.41
  20. Fiyinfolu O. Balogun · 2 shared papers, 2025–2026 · strength 0.39
  21. Carla Hajj · 2 shared papers, 2024–2026 · strength 0.39
  22. Danny N. Khalil · 2 shared papers, 2024–2026 · strength 0.39
  23. Peter James O'Dwyer · 7 shared papers, 2013–2019 · strength 0.36
  24. Marinela Capanu · 3 shared papers, 2020–2025 · strength 0.36
  25. Joshua S. Jolissaint · 2 shared papers, 2021–2025 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.